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Calcium channel blockers (CCBs) can
prevent cardiovascular events in patients
with coronary artery disease (CAD). This
study looked retrospectively at the
prognosis of CAD in hypertensive patients
with CAD who had undergone a coronary
angiograph, had been given a CCB
(benidipine [n = 66], amlodipine [n = 45],
or long-acting nifedipine [n = 31]) on
hospital discharge and were then followed
up for a mean ± SD of 5.2 ± 2.9 years.
Systolic/diastolic blood pressure for all 142
patients decreased significantly from a
mean ± SD of 137 ± 20/74 ± 15 mmHg to
129 ± 20/71 ± 12 mmHg. Major adverse
cardiovascular events (MACE) occurred in
15 patients. Chronic kidney disease (CKD)
was a significant risk factor for MACE
(hazard ratio 2.35, 95% confidence intervals
1.45, 3.80). Benidipine was superior to
nifedipine in preventing MACE in patients
both with and without CKD. In conclusion,
benidipine and amlodipine reduced the
frequency of MACE in hypertensive patients
with CAD, particularly in those with
complicating CKD.
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Introduction
Calcium channel blockers (CCBs) are widely
used in the treatment of angina pectoris and
hypertension, primarily based on their
actions as coronary artery vasodilators.
Long-acting CCBs have also been shown to
prevent cardiovascular events in
hypertensive patients.1,2 The CCBs are
known to be effective in reducing
cardiovascular mortality and morbidity in
patients with angina pectoris,3,4 especially
those with underlying hypertension.5,6
Ischaemic heart disease and myocardial
infarction in the Japanese population are
characterized by their frequent association
with coronary vasospasm.7,8 The CCBs have
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been shown to be highly effective in patients
with vasospastic angina,9 and studies have
demonstrated the effects of different CCBs on
the risk of developing cardiovascular events
in patients with vasospastic angina.10 – 12
Only limited information is available on
whether the effects of CCBs in preventing the
development of cardiovascular events might
vary with the drug class in patients with
coronary artery disease (CAD) associated
with organic stenosis.
In the present retrospective, observational
study, patients diagnosed with both
hypertension and CAD who were prescribed
CCBs at the time of discharge from hospital
were identified from a coronary angiography
database. The aim of the study was to
identify the risk factors for developing major
adverse cardiovascular events (MACE) and




Patients diagnosed with both hypertension
and CAD who were prescribed CCBs on the
day of discharge from hospital were
retrospectively identified from a database of
consecutive patients who underwent
coronary angiography between 1 January
1995 and 30 September 2006 at the
Department of Cardiovascular Medicine,
Toyama Red Cross Hospital, Toyama, Japan.
All patients fulfilling these criteria and for
whom follow-up data were available were
included in the analysis. A follow-up inquiry
about the patients’ present status, including
survival and complications, as of 1 January
2008 was carried out by mail and telephone
for all included patients. The study was
conducted with the approval of the
Institutional Review Board of Toyama Red
Cross Hospital. All participants (or their
representatives) provided written and verbal
informed consent to be included in the study.
In this study, CAD was defined as the
occurrence of ≥ 75% stenosis in at least one
principal coronary artery, in accordance
with the classification of the American Heart
Association,13 and hypertension was defined
as a systolic blood pressure of ≥ 140 mmHg
and/or a diastolic blood pressure of ≥ 90
mmHg, in accordance with the Japanese
Society of Hypertension Guidelines for the
Management of Hypertension.14 The doses of
CCBs were (mean ± SD): benidipine 6.7 ± 1.9
mg/day, amlodipine 5.1 ± 1.2 mg/day, and
nifedipine 40.6 ± 12.9 mg/day.
DATA COLLECTION
The database and medical records were
reviewed for patient characteristics at the
time of coronary angiography (baseline) and
for the angiographic findings. Details of the
treatment employed, such as percutaneous
coronary intervention, coronary artery
bypass grafting, and medications taken were
also collated from the medical records.
An estimated glomerular filtration rate, as
estimated from the serum creatinine
concentration using the Modification of Diet
in Renal Disease (MDRD) study equation, of
< 60 min/ml per 1.73 m2 for ≥ 3 months prior
to baseline was considered to be indicative of
chronic kidney disease (CKD).15 The
pressure–rate product (PRP) was calculated
by multiplying the systolic blood pressure
and the heart rate. The systolic, diastolic and
mean blood pressures, heart rate, PRP and
frequency of angina attacks as determined at
the last visit or at the onset of MACE were
compared with the values at baseline.
The location and extent of coronary
artery stenotic lesions in the coronary
angiograph obtained at baseline were
expressed according to the American Heart
Association classification.13 The presence of
stenosis in the principal coronary arteries,
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such as in the right coronary artery, left
circumflex artery and left anterior
descending artery, the number of vessels
showing stenotic lesions, and the presence of
significant multivessel stenosis were also
determined.
STUDY ASSESSMENTS
The primary outcome in this study was the
frequency of occurrence of MACE: cardiac
death, fatal or non-fatal myocardial
infarction, or unstable angina pectoris
requiring hospitalization. Patient
characteristics, coronary angiography
findings and treatment regimens at baseline
were assessed to identify risk factors for
MACE. Changes in the systolic, diastolic and
mean blood pressures, heart rate and PRP
from baseline to the last visit were evaluated
and their potential relationship with the
incidence of MACE determined.
Other outcomes included the incidence of
revascularization, incidence of fatal or non-
fatal stroke, and progression to end-stage
renal disease (ESRD). In this study, ESRD was
defined as a doubling of the baseline serum
creatinine concentration or a serum
creatinine concentration of ≥ 1.5 mg/dl.
Information on the nature and date of onset
of MACE occurring during the follow-up
period up to 1 January 2008 were also
collected. The influence of the patient
characteristics and the prophylactic effect of
each CCB against the development of MACE
were also assessed.
STATISTICAL ANALYSIS
Data were expressed as mean ± SD. Cox
regression analysis was used to identify the
factors determining the primary outcome,
namely, the frequency of development of
MACE. Kaplan–Meier survival curves of the
risk factors identified in relation to the CCBs
used were generated to estimate the time to
MACE. Changes in the systolic, diastolic and
mean blood pressures, heart rate and PRP
from the baseline to the last visit were
analysed using the paired t-test. Differences
in the frequency of angina attacks were
evaluated by Wilcoxon’s U-test and Mann–
Whitney’s U-test. Kaplan–Meier curves were
generated to compare the time-to-event
between the treatments and the data were
analysed by the log-rank test. Statistical
analyses were carried out using the SPSS®
statistical package, version 11.01J (SPSS Inc.,
Chicago, IL, USA) for Windows®. The two-




From the database, 164 patients diagnosed
with both hypertension and CAD and who
were prescribed CCBs on the day of hospital
discharge were identified and, of these, 142
patients had follow-up data available and
were included in the analysis. Patient
characteristics and angiographic findings at
the time of coronary angiography (baseline)
are shown in Table 1. Of the 142 patients
included in the analysis, 66 received
benidipine, 45 received amlodipine and 31
received nifedipine. There were no
significant differences among the three
treatment groups in baseline characteristics,
except for concurrent hyperlipidaemia.
Percutaneous coronary intervention was
carried out in 105 (74%) of the 142 patients.
Details of the treatment employed and
medications prescribed at discharge are
shown in Table 2. The use of different
interventional techniques, including balloon
angioplasty and stenting with a bare metal
stent or a drug-eluting stent, was similar
among the three treatment groups. Neither
the subject characteristics nor the CCBs used
were different before or after the introduction
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of drug-eluting stents. At baseline,
angiotensin II receptor blockers (ARBs) were
used most frequently in the nifedipine
treatment group (P < 0.001). The CCB dose at
baseline was (mean ± SD) 6.7 ± 1.9 mg/day
for benidipine, 5.1 ± 1.2 mg/day for
amlodipine and 40.6 ± 12.9 mg/day for
nifedipine. The proportion of patients who
continued to take a CCB until their last visit
was 44/66 (66.7%) in the benidipine group,
28/45 (62.2%) in the amlodipine group, and
21/31 (67.7%) in the nifedipine group.
STUDY OUTCOMES
The primary outcome, MACE, occurred in 15
patients, consisting of cardiac death in six
cases, non-fatal myocardial infarction in
four cases and unstable angina in five cases.
Three of the cardiac deaths were attributable
to myocardial infarction. Analysis of the risk
factors for MACE amongst all the patients
studied is shown in Table 3. The hazard ratio
for MACE was 2.35 (95% confidence
intervals [CI] 1.45, 3.80; P = 0.001) for those
with concurrent CKD and 0.94 (95% CI 0.89,
1.00; P = 0.038) for change in heart rate from
baseline. The incidence of MACE was
significantly higher in subjects with CKD
than in those without CKD (Fig. 1). The
effects of the three CCBs in preventing the
occurrence of MACE were compared in the
patients with CKD (n = 52) (Fig. 2).
Benidipine and amlodipine were
significantly more effective than nifedipine
(P = 0.004 and P < 0.001, respectively) in
preventing MACE in this population, just as
in the entire population.
Benidipine was associated with a low
hazard ratio of 0.28 (95% CI 0.08, 1.00; P =
0.049) for MACE, in contrast to a high
hazard ratio of 5.26 for nifedipine (95% CI
1.83, 15.15; P = 0.002) (Table 4). For all-cause
mortality, the hazard ratio was high in the
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Interestingly, benidipine decreased the
hazard ratio for progression to ESRD to 0.38,
although this did not reach statistical
significance in the population studied.
Kaplan–Meier curves were generated to
compare the time-to-event between the
treatments. There were no significant
differences in the duration of follow-up
(mean ± SD 5.2 ± 2.9 years; median 5.3
years) among the three groups. Benidipine
Hazard
Hazard ratio 95% CI
Statistical
Characteristic ratio Lower Upper significancea
Age, ≥ 65 years 1.08 0.38 3.04 NS
Sex, female 1.27 0.43 3.72 NS
Body mass index, ≥ 25 kg/m2 0.59 0.18 1.89 NS
Hyperlipidemia 1.76 0.62 4.96 NS
Diabetes mellitus 1.58 0.56 4.45 NS
Chronic kidney disease 2.35 1.45 3.80 P = 0.001
Previous myocardial infarction 1.32 0.47 3.69 NS
Previous stroke 1.01 0.23 4.48 NS
LVEF, < 50% 1.39 0.36 5.39 NS
Multivessel stenosis 1.44 0.52 3.97 NS
No. of vessels showing significant stenosis 1.45 0.76 2.76 NS
Percutaneous coronary intervention 0.68 0.24 1.92 NS
Balloon angioplasty 0.43 0.12 1.56 NS
Bare metal stent 1.01 0.34 3.01 NS
Drug-eluting stent 2.51 0.26 24.62 NS
Coronary artery bypass grafting 1.46 0.41 5.17 NS
Statins 1.64 0.58 4.65 NS
ARBs 1.52 0.32 7.32 NS
ACE inhibitors 2.10 0.59 7.48 NS
β-Blockers 0.92 0.21 4.08 NS
Systolic blood pressure at baseline 0.99 0.96 1.02 NS
Diastolic blood pressure at baseline 0.97 0.93 1.01 NS
Mean blood pressure at baseline 0.97 0.94 1.01 NS
Heart rate at baseline 0.98 0.90 1.06 NS
Pressure–rate product at baseline 1.00 1.00 1.00 NS
Change in systolic blood pressure 1.00 0.98 1.02 NS
Change in diastolic blood pressure 0.98 0.96 1.01 NS
Change in mean blood pressure 0.99 0.97 1.02 NS
Change in heart rate 0.94 0.89 1.00 P = 0.038
Change in pressure–rate product 1.00 1.00 1.00 NS
aThe identification of risk factors for MACE used univariate Cox regression analysis.
Coronary angiography carried out between January 1995 and September 2006, and followed up in January
2008.
Calcium channel blocker dose: (mean ± SD): benidipine 6.7 ± 1.9 mg/day; amlodipine, 5.1 ± 1.2 mg/day;
long-acting nifedipine, 40.6 ± 12.9 mg/day.
LVEF, left ventricular ejection fraction; ARBs, angiotensin II receptor blockers; ACE, angiotensin-converting
enzyme; NS, not statistically significant (P > 0.05); CI, confidence interval.
TABLE 3:
Analysis to identify the risk factors for major adverse cardiovascular events (MACE)
following coronary angiography and calcium channel blocker treatment after hospital
discharge in patients with coronary artery disease and hypertension (n = 142)
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and amlodipine were both significantly
superior to nifedipine (P < 0.001 and P =
0.018 respectively) in preventing the
development of MACE (Fig. 3A). The
FIGURE 1: The effect of chronic kidney disease on the time to a major adverse
cardiovascular event (MACE) in patients who also had coronary artery disease and
hypertension and underwent coronary angiography and discharge from hospital on a
calcium channel blocker (mean ± SD dose: benidipine 6.7 ± 1.9 mg/day, amlodipine
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FIGURE 2: Effect of the different calcium channel blockers on the time to occurrence
of a major adverse cardiovascular event (MACE) in patients with chronic kidney
disease (n = 52) who also had coronary artery disease and hypertension and
underwent coronary angiography (mean ± SD dose: benidipine 6.7 ± 1.9 mg/day,
amlodipine 5.1 ± 1.2 mg/day or long-acting nifedipine 40.6 ± 12.9 mg/day) (NS, not
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percentage of patients without cardiac death
was significantly higher in the benidipine (P
< 0.001) and amlodipine (P = 0.013) groups
than in the nifedipine group (Fig. 3B).
Patients treated with benidipine or
amlodipine showed significantly increased
survival (P = 0.004 and P = 0.043
respectively), estimated from the total
mortality, compared with those treated with
nifedipine (Fig. 3C). A significant difference
in the inhibitory effect against progression to
ESRD was noted between nifedipine and
benidipine (P = 0.034), although the
difference between nifedipine and
amlodipine was not statistically significant
(Fig. 3D).
CHANGE IN BLOOD PRESSURE,
HEART RATE AND PRP
The mean systolic/diastolic blood pressure
for all 142 patients decreased significantly (P
< 0.05) from 137 ± 20/74 ± 15 mmHg at the
time of coronary angiography (baseline) to
129 ± 20/71 ± 12 mmHg at the last follow-up
visit. The systolic, diastolic and mean blood
pressures, heart rate and PRP at baseline and
at the last follow-up visit for patients on each
of the three CCBs are shown in Table 5.
TABLE 4:
Prophylactic effect of calcium channel blockers on the occurrence of major adverse
cardiovascular events (MACE), cardiac death, all-cause mortality, stroke and end-stage
renal disease (ESRD) following coronary angiography in patients with coronary artery
disease and hypertension
No. (%) of Hazard
Hazard ratio 95% CI
Statistical
Event events ratio Lower Upper significancea
MACE
Benidipine (n = 66) 3 (4.5) 0.28 0.08 1.00 P = 0.049
Amlodipine (n = 45) 5 (11.1) 0.82 0.28 2.40 NS
Nifedipine (n = 31) 7 (22.6) 5.26 1.83 15.15 P = 0.002
Cardiac death
Benidipine (n = 66) 2 (3.0) 0.28 0.06 1.41 NS
Amlodipine (n = 45) 1 (2.2) 0.22 0.03 1.78 NS
Nifedipine (n = 31) 6 (19.4) 11.24 2.75 45.92 P < 0.001
All-cause mortality
Benidipine (n = 66) 5 (7.6) 0.36 0.13 1.01 NS
Amlodipine (n = 45) 7 (15.6) 0.91 0.36 2.32 NS
Nifedipine (n = 31) 8 (25.8) 3.83 1.53 9.57 P = 0.004
Stroke
Benidipine (n = 66) 5 (7.6) 0.74 0.24 2.27 NS
Amlodipine (n = 45) 5 (11.1) 1.09 0.36 3.34 NS
Nifedipine (n = 31) 3 (9.7) 1.39 0.38 5.09 NS
ESRD
Benidipine (n = 66) 4 (6.1) 0.38 0.12 1.17 NS
Amlodipine (n = 45) 7 (15.6) 1.22 0.45 3.30 NS
Nifedipine (n = 31) 5 (16.1) 2.85 0.97 8.44 NS
aThe identification of risk factors for MACE used univariate Cox regression analysis.
Coronary angiography carried out between 1 January 1995 and 30 September 2006, and followed up on 1
January 2008.
Calcium channel blocker dose (mean ± SD): benidipine 6.7 ± 1.9 mg/day; amlodipine, 5.1 ± 1.2 mg/day;
long-acting nifedipine, 40.6 ± 12.9 mg/day.
CI, confidence interval; NS, not statistically significant (P > 0.05).
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Significant lowering of systolic blood
pressure at the last follow-up visit compared
with baseline was observed for all three
treatments (P = 0.044, P = 0.044 and P =
0.016 for benidipine, amlodipine and
nifedipine, respectively), whereas the
decrease from baseline in heart rate was only
statistically significant in the benidipine
group (P = 0.004). A significant decrease in
the PRP was also observed in the benidipine
(P < 0.001), amlodipine (P = 0.046) and
nifedipine groups (P = 0.028).
Discussion
The incidence of MACE has been shown to
rise with increasing severity of CKD.16 This
was confirmed by the present study, where
the frequency of MACE was higher in
patients with concurrent CKD. It is
noteworthy that benidipine not only
significantly suppressed progression to ESRD
in CAD patients compared with nifedipine,
but also reduced the incidence of MACE in
CAD patients with CKD, the effects being
more pronounced than those of nifedipine.
Studies have shown that benidipine is more
useful than other CCBs for prophylaxis
against MACE in patients with vasospastic
angina.10 – 12 Indeed, this may contribute to a
reduction in the frequency of MACE in CAD
patients because CAD in Japan is
characterized by a high incidence of coronary
FIGURE 3: Influence of different calcium channel blockers on the time to: (A) a major
adverse cardiovascular event (MACE); (B) cardiac death; (C) total mortality; or (D)
end-stage renal disease (ESRD) after coronary angiography in patients with coronary
artery disease and hypertension (mean ± SD dose: benidipine 6.7 ± 1.9 mg/day,
amlodipine 5.1 ± 1.2 mg/day or long-acting nifedipine 40.6 ± 12.9 mg/day) (NS, not
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spasm (about 80%).7,8 In the present study,
benidipine was shown to reduce the incidence
of MACE in CAD patients. According to the
Japan Multicenter Investigation for
Cardiovascular Diseases B (JMIC-B) Study
Group, long-acting dihydropyridine CCBs can
improve the prognosis in CAD patients,17
particularly those with underlying
hypertension.5 One study in Japanese patients
demonstrated a beneficial effect of benidipine
on survival after myocardial infarction
compared with the effects of short-acting
nisoldipine and nifedipine.18 The present study
extended these findings, by demonstrating the
protective effect of long-acting CCBs, such as
benidipine and amlodipine, against MACE in
hypertensive patients with CAD.
The better prognosis of CAD patients
receiving benidipine compared with those
receiving nifedipine could be attributable to
the following actions of benidipine. First,
benidipine acts more selectively on the
coronary vessels than nifedipine.19 This
selective action on the coronary vessels
increases the myocardial oxygen supply,
resulting in a potent inhibition of
myocardial damage. Secondly, benidipine
exerts a vasodilatory effect of slower onset
than nifedipine,20 which makes it less liable
to enhance sympathetic nerve activity than
TABLE 5:
Blood pressure, heart rate and the pressure–rate product at the time of coronary
angiography (baseline) compared with at the last follow-up visit in patients with coronary
artery disease and hypertension, stratified according to calcium channel blocker treatment
after hospital discharge
Last follow-up Statistical
Treatment/parameter Baseline visit significancea
Benidipine (n = 66)
Systolic blood pressure (mmHg) 135.7 ± 23.3 128.7 ± 21.1 P = 0.044
Diastolic blood pressure (mmHg) 72.6 ± 14.7 70.3 ± 10.6 NS
Mean blood pressure (mmHg) 93.6 ± 16.0 89.8 ± 12.8 NS
Heart rate (beats/min) 76.6 ± 13.5 66.8 ± 10.5 P = 0.004
Pressure–rate product (mmHg beats/min) 10 298.1 ± 2956.4 7779.7 ± 1931.0 P < 0.001
Amlodipine (n = 45)
Systolic blood pressure (mmHg) 137.7 ± 19.8 127.9 ± 22.7 P = 0.044
Diastolic blood pressure (mmHg) 77.3 ± 17.7 71.4 ± 13.3 NS
Mean blood pressure (mmHg) 97.4 ± 16.7 90.3 ± 15.8 NS
Heart rate (beats/min) 73.1 ± 13.2 72.1 ± 11.8 NS
Pressure–rate product (mmHg beats/min) 10 565.6 ± 2473.0 8647.2 ± 2378.5 P = 0.046
Nifedipine (n = 31)
Systolic blood pressure (mmHg) 137.9 ± 15.5 128.2 ± 15.1 P = 0.016
Diastolic blood pressure (mmHg) 72.8 ± 10.0 70.1 ± 12.8 NS
Mean blood pressure (mmHg) 94.5 ± 10.2 89.5 ± 12.6 NS
Heart rate (beats/min) 74.3 ± 6.7 70.0 ± 11.3 NS
Pressure–rate product (mmHg beats/min)10 671.1 ± 1868.7 8836.9 ± 1503.3 P = 0.028
aComparison between baseline and last follow-up visit used the paired t-test.
Coronary angiography carried out between 1 January 1995 and 30 September 2006, and followed up on 1
January 2008.
Calcium channel blocker dose (mean ± SD): benidipine 6.7 ± 1.9 mg/day; amlodipine, 5.1 ± 1.2 mg/day;
long-acting nifedipine, 40.6 ± 12.9 mg/day.
NS, not statistically significant (P > 0.05).
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